OS Therapies (OSTX) vs Pelthos Therapeutics (PTHS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
OS Therapies (OSTX) has outperformed Pelthos Therapeutics (PTHS) over the past year, losing 20.6% versus a loss of 24.5%. Pelthos Therapeutics is the larger company by market cap ($78.5 million vs $75.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OSTX | PTHS |
|---|---|---|
| Share price | $1.62 | $20.50 |
| Market cap | $75.82M | $78.48M |
| 1-day change | +4.52% | -2.33% |
| YTD return | +15.71% | -33.87% |
| 1-year return | -20.59% | -24.47% |
| Forward P/E | 4.67 | — |
| EPS (TTM) | $-1.08 | $-27.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.25 | $37.50 |
| 52-week low | $1.15 | $18.19 |
| Distance from 52-week high | -28.00% | -45.33% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +424.69% | +159.22% |
| Average volume | 586.70K | 60.07K |
| Shares outstanding | 46.81M | 3.83M |
| Employees | 4 | 92 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About OS Therapies
OSTX stock →OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Pelthos Therapeutics
PTHS stock →Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 92 employees
OSTX vs PTHS FAQ
Which is bigger, OS Therapies or Pelthos Therapeutics?
Pelthos Therapeutics (PTHS) is larger, with a market capitalization of $78.48M compared with $75.82M for OS Therapies (OSTX).
Which stock has performed better over the past year, OSTX or PTHS?
OSTX returned -20.59% over the past 12 months, compared with -24.47% for PTHS (price return, excluding dividends). Past performance does not predict future results.
Are OS Therapies and Pelthos Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for OS Therapies and Biotechnology: Biological Products (No Diagnostic Substances) for Pelthos Therapeutics.